Immunotherapy plus chemo shows promise in Triple-Negative breast cancer trial
NCT ID NCT07283692
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial is testing whether adding the immunotherapy drug serplulimab to standard chemotherapy before surgery can improve outcomes for people with triple-negative breast cancer. The study will enroll 46 participants and measure how many achieve a complete response (no cancer cells left in the removed tissue). It also tracks side effects to assess safety.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Serplulimab (an immunotherapy drug) combined with paclitaxel and carboplatin (chemotherapy drugs)
What this could lead to
If successful, this combination could become a new standard neoadjuvant treatment for triple-negative breast cancer, potentially increasing the chance of a complete response before surgery.
What could go wrong
This is an early-phase, single-arm trial with only 46 participants, so results may not apply broadly. Immunotherapy can cause immune-related side effects, and the added benefit over existing treatments is not yet proven.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TRIPLE NEGATIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Renji Hospital, School of Medicine, Shanghai Jiaotong University
RECRUITINGShanghai, 200127, China
Contact Phone: •••-•••-•••• Email: •••••@•••••